Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Svizzera | Salute | Prodotti farmaceutici | 675,07 Mrd CHF | 108,1x | 8,17 | 750 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Roche Holding | Svizzera | Salute | Prodotti farmaceutici | 230,59 Mrd CHF | 20,4x | -6,34 | 289,40 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,2% Ribasso | Fai l’upgrade a Pro+ | |
Roche Holding Participation | Svizzera | Salute | Prodotti farmaceutici | 215,61 Mrd CHF | 21,8x | -6,34 | 270,60 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,2% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 196,69 Mrd CHF | 14,6x | 0,2 | 97,15 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,6% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 196,69 Mrd CHF | 14,6x | 0,2 | 97,44 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Sandoz | Svizzera | Salute | Prodotti farmaceutici | 15,16 Mrd CHF | -2.379,2x | 22,21 | 35,27 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,4% Rialzo | Fai l’upgrade a Pro+ | |
Siegfried Holding Ltd | Svizzera | Salute | Prodotti farmaceutici | 4,88 Mrd CHF | 37,7x | -2,64 | 1.138 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 0,7% Rialzo | Fai l’upgrade a Pro+ | |
Galenica Sante | Svizzera | Salute | Prodotti farmaceutici | 3,71 Mrd CHF | 21x | -0,65 | 74,45 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,5% Rialzo | Fai l’upgrade a Pro+ | |
Dottikon Es Holding AG | Svizzera | Salute | Prodotti farmaceutici | 3,58 Mrd CHF | 44,5x | -5,44 | 259 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Joincare Pharmaceutical DRC | Svizzera | Salute | Prodotti farmaceutici | 2,66 Mrd CHF | 13,4x | -2,38 | 6,73 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
COSMO Pharma | Svizzera | Salute | Prodotti farmaceutici | 1,21 Mrd CHF | 18,4x | 0,03 | 75,10 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,1% Rialzo | Fai l’upgrade a Pro+ | |
PolyPeptide Group AG | Svizzera | Salute | Prodotti farmaceutici | 1,01 Mrd CHF | -38,7x | -1,79 | 30,50 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,6% Ribasso | Fai l’upgrade a Pro+ | |
Newron Pharmaceuticals | Svizzera | Salute | Prodotti farmaceutici | 144,85 Mln CHF | -7,8x | 0,5 | 7,60 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Santhera Pharmaceuticals Holding | Svizzera | Salute | Prodotti farmaceutici | 107,14 Mln CHF | 1,5x | 0,01 | 8,85 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Spexis | Svizzera | Salute | Prodotti farmaceutici | 2,71 Mln CHF | -0,1x | -0,04 | 0,04 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |